{"schema_version":"secwatch.filing_event.v1","accession":"0001185185-24-000301","form_type":"8-K","ticker":"IGC","cik":"0001326205","company_name":"IGC Pharma, Inc.","filed_at":"2024-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.783428+00:00","generated_at":"2026-06-04T08:59:16.630604+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"IGC Pharma enters ATM sales agreement for up to $60M in common stock","bullets":["Agreement with A.G.P./Alliance Global Partners allows at-the-market sales of up to $60 million in common stock.","Board initially reserved 171,428,571 shares based on $0.35 reference price; commission set at 3.0% of gross proceeds.","Sales may occur from time to time via NYSE American; agent not obligated to purchase shares on principal basis.","Annual maintenance fee of $10,000 payable to sales agent; agreement terminates after three years or earlier by notice."],"urls":{"canonical":"https://secwatch.observer/filing/0001185185-24-000301","json":"https://secwatch.observer/filing/0001185185-24-000301.json","markdown":"https://secwatch.observer/filing/0001185185-24-000301.md","text":"https://secwatch.observer/filing/0001185185-24-000301.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326205/000118518524000301/0001185185-24-000301-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326205/000118518524000301/igcpharma20240320c_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T08:59:16.630604+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0bb210faa547280ec93b982ed1cb17896b841191","claim":"IGC Pharma, Inc. entered into Sales Agreement with A.G.P./Alliance Global Partners valued at aggregate offering price subject to certain limitations on the amount of Common Stock that may be of (effective 2024-03-19).","evidence_excerpt":"On March 19, 2024, IGC Pharma, Inc. (the “Company”) entered into a new Sales Agreement (the “Agreement”) with A.G.P./Alliance Global Partners (the “Agent”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326205/000118518524000301/0001185185-24-000301-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"A.G.P./Alliance Global Partners"},{"label":"Value","value":"aggregate offering price subject to certain limitations on the amount of Common Stock that may be of"},{"label":"Effective","value":"2024-03-19"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}